Emerging infectious diseases, like COVID-19 and Ebola, pose an ever-present threat to global health. The World Health Organization's R&D Blueprint is a crucial tool in this ongoing battle, prioritizing research and development for pathogens with the highest potential to cause widespread epidemics. However, limited resources and the specter of unknown "Disease X" threats underscore the urgency and complexity of this task.

Biosynth plays a vital role in this endeavor by providing high-quality raw materials essential for the development of in-vitro diagnostics (IVD). These IVD tests are critical for early detection, surveillance, and containment of infectious diseases. Biosynth's offerings include a vast array of proteins, antibodies, and biospecimens, including reagents for emerging viruses like Monkeypox and Zika. Moreover, our custom manufacturing capabilities and commitment to quality make us a valuable partner for researchers and diagnostic companies working on the front lines of epidemic preparedness. Biosynth's dedication to supporting R&D efforts in infectious diseases highlights the importance of collaboration between industry, academia, and governments to address the complex challenges posed by existing and emerging pathogens.

Learning Objectives

• Understand the current landscape of emerging infectious diseases. Participants should be able to identify key trends, challenges, and opportunities in the field of emerging diseases.

• Gain insights into the role of diagnostics and biotechnology in combating emerging diseases. Participants should appreciate the importance of rapid and accurate diagnostics, as well as the potential of innovative biotechnological solutions.

• Explore strategies for preparedness and response to future outbreaks. Participants should be able to discuss the importance of proactive measures and the role of collaboration in mitigating the impact of emerging diseases.